So-Young International Inc.
NASDAQ:SYMedical - Healthcare Information Services
-$0.09 today
- Market cap
- $239.36M
- Beta
- 1.98
- P/E (TTM)
- -5.0
- EPS (TTM)
- -$1.95
Volume 0.46M
Average 0.63M
SY Net Income
Bottom-line profit, the starting point for calculating cash from operations.
So-Young International Inc.NASDAQ: SY
Net Income · Q4 FY2025 · quarter ended Dec 2025
Net income declines year over year
Q4 FY2025 net income of CN¥113.45M (cash outflow) fell 81.3% year over year, behind the -58.1% change in trailing-twelve-month net income. Sequentially, it rose 76.5% from the prior quarter. Over 3 fiscal years it compounded at +55.2% a year.
Context
- Net income amounted to 16.7% of revenue in FY2025, down 23.4 pp from a year earlier.
- Net income increased in 2 of the last 3 fiscal years.
What to watch
Whether net income reaches the consensus estimate from 2 analysts of -CN¥206.31M (-16.4%) for the fiscal year ending Dec 2026, a step up from the -58.0% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterDec 2025
- -CN¥113.45M+76.5% QoQ
- Last fiscal yearDec 2025
- -CN¥246.91M-58.0% YoY
- LTMDec 2025
- -CN¥246.9M-58.1% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -81.3% | +187.5% | +268.8 pp |
| 1 year | -58.0% | -16.4% | +41.5 pp |
| 3-year CAGR | +55.2% | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
CNY · from the cash flow
- Latest · FY2025
- (246.91M) CNY
- Year-over-year change
- +58.0%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (246.91M) | +58.0% |
| FY2024 | 2024-12-31 | (587.18M) | -2363.3% |
| FY2023 | 2023-12-31 | 25.94M | +139.2% |
| FY2022 | 2022-12-31 | (66.11M) | -75.6% |
| FY2021 | 2021-12-31 | (37.64M) | — |
Net Income vs competitors
How SY compares with its peers on the latest reported figures
- Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -58.1% is the 9th highest of 11, against a peer median of +23.7%.
- Net income amounts to 16.3% of revenue for SY, versus a peer median of 84.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Dec 2025 | CN¥246.9M CNY | -58.1% | +55.2% | 16.3% | |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | $222.39M USD | -13.8% | +21.9% | — |
| LTM Mar 2026 | $221.04M USD | +23.7% | — | — | |
| LTM Mar 2026 | $136.99M USD | -8.6% | -3.2% | 173.0% | |
| LTM Mar 2026 | $100.48M USD | +131.9% | +10.0% | 24.4% | |
| LTM Apr 2026 | $82.7M USD | +98.8% | — | 9.6% | |
| LTM Mar 2026 | $81.36M USD | +148.9% | -73.6% | 822.4% | |
| LTM Mar 2026 | $80.17M USD | +23.8% | -3.4% | 98.8% | |
| LTM Mar 2026 | $78.21M USD | +158.9% | -26.7% | 90.7% | |
| LTM Feb 2026 | $62.79M USD | -964.8% | — | 78.0% | |
| LTM Mar 2026 | $26.09M USD | -85.3% | -21.0% | 37.5% | |
| Peer median (excluding SY) | — | +23.7% | -3.4% | 84.3% | |
Competitors are the stored peer set for SY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (37.64M) | (66.11M) | 25.94M | (587.18M) | (246.91M) |
| Depreciation & Amortization | 30.08M | 47.09M | 46.09M | 45.92M | 57.21M |
| Deferred Income Tax | 1.65M | (24.8M) | (33.52M) | (16.17M) | (1.79M) |
| Stock-Based Compensation | 106.15M | 43.34M | 36.32M | 32.66M | 8.92M |
| Change in Working Capital | (164.54M) | (195M) | (122.45M) | (167.85M) | (26.11M) |
| Accounts Receivables | 14.58M | 13.56M | (28.95M) | (61.48M) | 29.72M |
| Inventory | 7.87M | (27.99M) | (2.12M) | (36.75M) | (115.98M) |
| Accounts Payables | (158.37M) | 0 | 0 | 0 | 0 |
| Other Working Capital | (28.61M) | (180.58M) | (91.37M) | (69.62M) | 60.14M |
| Other Non-Cash Items | 148.58M | 82.62M | 70.11M | 666.99M | 103.29M |
| Operating Cash Flow | 84.29M | (112.87M) | 22.5M | (25.63M) | (105.39M) |
| Capital Expenditures | (45.06M) | (15.71M) | (51.18M) | (62.55M) | (196.62M) |
| Acquisitions (Net) | (636.87M) | (97.49M) | 0 | 0 | 0 |
| Purchases of Investments | (2.02B) | (1.21B) | (2.27B) | (1.22B) | (872.29M) |
| Sales of Investments | 3.05B | 764.79M | 2.1B | 1.53B | 1.03B |
| Other Investing Activities | (8.37M) | (18.03M) | 17.16M | 10.85M | 500K |
| Investing Cash Flow | 339.82M | (572.21M) | (202.61M) | 257.04M | (42.81M) |
| Debt Repayment | 0 | 0 | 29.83M | 40M | (30M) |
| Common Stock Issued | 0 | 0 | 0 | 0 | 79K |
| Common Stock Repurchased | (217.71M) | (15.12M) | (125.62M) | (18.24M) | (15.25M) |
| Dividends Paid | 0 | 0 | 0 | (43.57M) | (19.03M) |
| Other Financing Activities | 969K | 1.54M | (4.22M) | 298K | 500K |
| Financing Cash Flow | (216.74M) | (13.59M) | (100.02M) | (21.51M) | (63.7M) |
| Effect of Forex Changes | (9.24M) | 55.86M | 11.87M | 3.34M | (1.48M) |
| Net Change in Cash | 198.12M | (642.81M) | (268.26M) | 213.23M | (213.38M) |
| Free Cash Flow | 39.23M | (128.58M) | (28.68M) | (88.18M) | (302.01M) |
So-Young International Inc.
NASDAQ:SY
Intrinsic Alpha fair value
Locked
Current Price
$1.83
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.